Screener
Veracyte VCYT R&D
R&D at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Veracyte’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:07 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001384101-26-000031
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Total cost of revenue | 37,912 | 34,965 |
| Gross profit | 101,159 | 79,508 |
| Operating expenses: | ||
| Research and development | 27,098 | 17,720 |
| Selling and marketing | 27,156 | 24,454 |
| General and administrative | 23,680 | 33,808 |
| Intangible asset amortization - operating expenses | 579 | 622 |
| Total operating expenses | 78,513 | 76,604 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Veracyte's R&D?
- Veracyte (VCYT) reported R&D of $27.1M in Q1 2026.
- How has Veracyte's R&D changed year-over-year?
- Veracyte's R&D increased by 52.9% year-over-year, from $17.72M to $27.1M.
- What is the long-term trend for Veracyte's R&D?
- Over 4 years (2021 to 2025), Veracyte's R&D has grown at a 24.1% compound annual growth rate (CAGR), from $29.84M to $70.81M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Veracyte's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude